Get the Weekly Intelligence Brief — top committee picks every Sunday.
TFX · NYSE · STOCK

Teleflex (TFX) Stock Analysis

Healthcare Updated September 17, 2026
$128.06
52W $100.18 – $145.00
52/100
$5.71B
-5.5
0.81
AI Committee Verdict
Watch
52/100
Conviction: Contested · 40% agreement · 5 analysts
+3.1%
-6.1%
0.51:1
Contested

Is TFX Bullish or Bearish?

Mixed. Innellis AI committee rates Teleflex Incorporated (TFX) Watch with a composite score of 52/100 , based on 5 analysts with 40% agreement. Last updated September 17, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +7.56 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -12.44 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.27 across 11 articles, 14d). Technical Analyst remains cautious — rsi at 21 is in oversold territory (could mean either capitulation or a bounce setup). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • News sentiment is positive (+0.27 across 11 articles, 14d) — News
Bear Case
  • ROE of only -31.9% -- cheap may mean cheap for a reason — Value
  • Revenue declining -14.5% YoY -- this is not a growth story right now — Growth
  • RSI at 21 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 17, 2026
Overall Committee Score
52/100
Agreement
40%
Analysts
5
Conviction
Contested
Sector Rank
Top 85%
of 192 Healthcare peers
Value Analyst neutral
42 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -31.9% -- cheap may mean cheap for a reason
Growth Analyst neutral
50 / 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− Revenue declining -14.5% YoY -- this is not a growth story right now
Technical Analyst bearish
38 / 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 21 is in oversold territory (could mean either capitulation or a bounce setup)
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 11 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2514.55)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 52.4 to 52.4.

Comparing 2026-09-16 to 2026-09-17 (1 day apart).

Technical Analysis

RSI (14)
21.1
Oversold
MACD Histogram
-1.336
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$121.22
Resistance
$133.13
Bollinger %B
0.02
Inside Bands
Price vs Moving Averages
EMA 9
$133.57 Below
EMA 21
$135.41 Below
EMA 50
$134.70 Below
EMA 200
$128.63 Below

Fundamental Analysis

Valuation
98
Growth
66
Profitability
21
Financial Health
88
Cash Flow
70
Valuation
P/E Ratio -5.5×
P/B Ratio 1.94×
PEG Ratio -0.29
Dividend Yield 1.05%
52W High $145.00
52W Low $100.18
Quality & Growth
ROE -2898.3%
ROA -1303.6%
Gross Margin 5376.5%
Operating Margin 334.9%
Revenue Growth YoY
Debt / Equity 0.99
AI Fundamental Assessment
P/E ratio of -5.5 (inexpensive relative to a 15-40x range); Price-to-book of 1.9x; PEG ratio of -0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -29.0%; Return on assets of -13.0%; Net margin of -39.6%; Gross margin of 53.8%; Current ratio of 2.60 (healthy short-term liquidity); Debt-to-equity of 0.99; Free cash flow per share is positive (8.97); Most recent quarter beat estimates by 36.0%; 2 consecutive earnings beats; EPS growth accelerating (-28.0% -> +26.6% QoQ); Analyst estimates falling over recent quarters
Get the Full TFX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime